Mean residence time for drugs subject to enterohepatic cycling
- PMID: 2810071
- DOI: 10.1007/BF01061900
Mean residence time for drugs subject to enterohepatic cycling
Abstract
A physiologically realistic model of enterohepatic cycling (EHC) which includes separate liver and gallbladder compartments, discontinuous gallbladder emptying and first-order absorption from both an oral formulation and secreted bile (kapo and kab, respectively) has been developed. The effect of EHC on area under the first-moment curve (AUMC) of drug concentration in plasma and on parameters derived from the AUMC was investigated. Unlike AUC, AUMC is dependent on the time and time-course of gallbladder emptying, increasing as the interval between gallbladder emptying increases. Consequently, mean residence time (MRT) is also a time-dependent parameter. Analytical solutions for MRTiv and MRTpo were derived. Mean absorption time (MAT = MRTpo - MRTiv) is also time-dependent, contrary to findings previously published for a model of EHC with a continuous time lag. MAT is also dependent on kapo, kba and the hepatic extraction ratio. The difference between MRTpos for two formulations with unequal kapo values may deviate from the difference in the inverse of their absorption rate constants. Implications for design and interpretation of pharmacokinetic studies include (i) MAT values may be dominated by the time-course of recycling rather than the time-course of the initial absorption, depending on the extent of EHC and (ii) the unpredictable nature of the time of gallbladder emptying will contribute to intrasubject variability in derived parameters during crossover studies. Knowledge of the extent of EHC is invaluable in deciding whether modification of the in vitro release characteristics of an oral formulation will have any effect on the overall time-course of absorption in vivo. Techniques to monitor or control gallbladder emptying may be helpful for reducing variability in pharmacokinetic studies for compounds which are extensively cycled in bile.
Similar articles
-
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.Clin Pharmacokinet. 2002;41(10):751-90. doi: 10.2165/00003088-200241100-00005. Clin Pharmacokinet. 2002. PMID: 12162761 Review.
-
A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.J Pharmacokinet Pharmacodyn. 2003 Apr;30(2):119-44. doi: 10.1023/a:1024415730100. J Pharmacokinet Pharmacodyn. 2003. PMID: 12942684
-
An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism, and intestinal elimination.Pharm Res. 1987 Jun;4(3):195-9. doi: 10.1023/a:1016447826075. Pharm Res. 1987. PMID: 3509282
-
A Gallbladder-Based Enterohepatic Circulation Model for Pharmacokinetic Studies.Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):493-504. doi: 10.1007/s13318-018-0535-1. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30488336
-
Efficiency of enterohepatic circulation, its determination and influence on drug bioavailability.Arzneimittelforschung. 1999 Oct;49(10):805-15. doi: 10.1055/s-0031-1300506. Arzneimittelforschung. 1999. PMID: 10554656 Review.
Cited by
-
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.Clin Pharmacokinet. 2002;41(10):751-90. doi: 10.2165/00003088-200241100-00005. Clin Pharmacokinet. 2002. PMID: 12162761 Review.
-
An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.Pharm Res. 1992 Feb;9(2):169-77. doi: 10.1023/a:1018968819366. Pharm Res. 1992. PMID: 1553336
-
Physiologically based structure of mean residence time.ScientificWorldJournal. 2012;2012:610631. doi: 10.1100/2012/610631. Epub 2012 Apr 1. ScientificWorldJournal. 2012. PMID: 22566773 Free PMC article.
-
Multiple peaking phenomena in pharmacokinetic disposition.Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481648 Review.
-
Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.Br J Clin Pharmacol. 2000 Mar;49(3):223-30. doi: 10.1046/j.1365-2125.2000.00162.x. Br J Clin Pharmacol. 2000. PMID: 10718777 Free PMC article. Clinical Trial.